Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 16
1966 38
1967 52
1968 76
1969 92
1970 149
1971 147
1972 117
1973 97
1974 109
1975 144
1976 121
1977 123
1978 142
1979 185
1980 149
1981 150
1982 193
1983 171
1984 223
1985 208
1986 191
1987 184
1988 129
1989 189
1990 214
1991 179
1992 191
1993 206
1994 216
1995 223
1996 229
1997 214
1998 237
1999 240
2000 316
2001 344
2002 411
2003 445
2004 467
2005 497
2006 568
2007 581
2008 553
2009 686
2010 836
2011 941
2012 1062
2013 1136
2014 1232
2015 1326
2016 1234
2017 1438
2018 1368
2019 1494
2020 1739
2021 1707
2022 1493
2023 1368
2024 508

Text availability

Article attribute

Article type

Publication date

Search Results

26,481 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
The Treatment of Advanced Melanoma: Therapeutic Update.
Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M. Villani A, et al. Int J Mol Sci. 2022 Jun 7;23(12):6388. doi: 10.3390/ijms23126388. Int J Mol Sci. 2022. PMID: 35742834 Free PMC article. Review.
Melanoma Cellular Plasticity.
Novak D, Utikal J. Novak D, et al. Int J Mol Sci. 2022 Jun 8;23(12):6401. doi: 10.3390/ijms23126401. Int J Mol Sci. 2022. PMID: 35742846 Free PMC article.
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Garbe C, et al. Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1. Nat Med. 2023. PMID: 37193799 No abstract available.
Trametinib (GSK1120212).
Zeiser R, Andrlová H, Meiss F. Zeiser R, et al. Recent Results Cancer Res. 2018;211:91-100. doi: 10.1007/978-3-319-91442-8_7. Recent Results Cancer Res. 2018. PMID: 30069762 Review.
Cobimetinib (GDC-0973, XL518).
Andrlová H, Zeiser R, Meiss F. Andrlová H, et al. Recent Results Cancer Res. 2018;211:177-186. doi: 10.1007/978-3-319-91442-8_12. Recent Results Cancer Res. 2018. PMID: 30069767 Review.
Targeting ferroptosis in melanoma: cancer therapeutics.
Khorsandi K, Esfahani H, Ghamsari SK, Lakhshehei P. Khorsandi K, et al. Cell Commun Signal. 2023 Nov 23;21(1):337. doi: 10.1186/s12964-023-01296-w. Cell Commun Signal. 2023. PMID: 37996827 Free PMC article. Review.
26,481 results
You have reached the last available page of results. Please see the User Guide for more information.